REG - Haleon PLC - Board and Committee Changes

HALEONAnnouncement

Mon 10:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251215:nRSO5757La&default-theme=true

RNS Number : 5757L  Haleon PLC  15 December 2025

 

 

Haleon plc: Board and Committee Changes

 

15 December 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces that Alan Stewart will succeed Vindi Banga as Senior Independent
Director ("SID"), upon Vindi's appointment as Chair with effect from 1 January
2026.

 

Alan Stewart joined the Board as a Non-Executive Director and Chair of the
Audit & Risk Committee in September 2024. Alan will remain Chair of the
Audit & Risk Committee and a member of the Remuneration Committee,
Nominations & Governance Committee and Environmental & Social
Sustainability Committee following his appointment as Senior Independent
Director.

 

In accordance with the UK Corporate Governance Code 2024, Vindi will step down
as a member of the Audit & Risk Committee effective 31 December 2025.
Vindi will also step down as a member of the Remuneration Committee effective
31 December 2025 and be appointed Chair of the Nominations & Governance
Committee effective 1 January 2026.

 

Further to the announcement on 10 November 2025, the Company confirms that
Vindi Banga's remuneration as Chair will be £757,103 per annum. Further
details will be disclosed in the Company's 2025 Annual Report & Accounts.

 

The Company confirms that there is no further information to be disclosed
under the requirements of UKLR 6.4.6R.

 

Amanda Mellor

Company Secretary

 

Enquiries

 

 Investors                                    Media

 Jo Russell              +44 7787 392441      Zoë Bird            +44 7736 746167
 Rakesh Patel            +44 7552 484646      Victoria Durman     +44 7894 505730

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans six major categories - Oral Health, Vitamins, Minerals and Supplements
(VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin
Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on
trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPGRGPUPAUBA



            Copyright 2019 Regulatory News Service, all rights reserved